Private equity firm Antin Infrastructure Partners (Euronext Paris:ANTIN) announced on Thursday that it has agreed to acquire Emsere from Dutch family investment platform Gryphion.
Emsere, headquartered in Leiden in the Netherlands, is a medical equipment rental specialist providing clinical trial equipment and logistics solutions to pharmaceutical companies and contract research organisations (CROs) globally.
Founded in 1996, Emsere manages over 13,000 pieces of equipment and delivers to more than 100 countries, serving six of the top 10 global pharmaceutical companies and seven of the top 10 CROs. Its portfolio includes centrifuges, imaging devices, cardiovascular and respiratory monitors, and cardio-pulmonary exercise testing equipment.
The company operates in the growing clinical trial equipment rental market, addressing demand for outsourced, complex, and regulatory-compliant solutions delivered at scale. Emsere's services allow clients to focus on scientific and clinical execution while avoiding capital expenditure and logistical coordination.
Antin's investment marks the eighth for its EUR2.2bn Mid Cap Fund I and continues its strategy of scaling health and medical infrastructure companies in Europe and North America. Emsere's CEO Patrice Gerard and senior management will co-invest alongside Antin.
The transaction is expected to close in the first quarter of 2026.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA